China Biologic Products (CBPO +0.9) moves up on positive comments out of Aegis Capital this...

|By:, SA News Editor

China Biologic Products (CBPO +0.9) moves up on positive comments out of Aegis Capital this morning. The firm raised its price target to $22 on the shares after China's National Development and Reform Commission announced a new round of retail price adjustments. The price ceilings for plasma-based products were raised, more notably, prices for various doses of human albumin would see an increase of over 5%. Human albumin represents 54.5% and 45.3% of China Biologic's 2011 and 9-month 2012 total revenue, respectively.